BCAXBicara Therapeutics Inc.
Price
+68%1YEnd-of-day closes, not the intraday tick.
The five questions
2 of 5 availableOnly two of the five can be answered for BCAX today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Watch
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?Mixed
We are a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. We have built a platform designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site. This dual-targeting approach both enhances drug exposure within the tumor microenvironment, or TME, and limits systemic toxicity.
In the company’s own words · 10-K filed Mar 30, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
The next results filing is expected around Nov 9, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 25, 2026On August 21, 2026, Bicara Therapeutics Inc. (the “Company”) entered into a Sub-Sublease Agreement (the “Sublease”) with Wayfair LLC, as sublandlord (the “Sublandlord”), pursuant to which the Company, as subtenant, will lease approximately 35,090 square feet of office space for new corporate headquarters to be located …Material agreement entered · Form 8-K
- Jul 28, 2026Resignation of Kiran Mazumdar-Shaw On July 23, 2026, Kiran Mazumdar-Shaw resigned from the Board of Directors (the “Board”) of Bicara Therapeutics Inc. (the “Company”) and her position on the Nominating and Corporate Governance Committee of the Board (the “Nominating and Corporate Governance Committee”), effective as …Director or officer change · Form 8-K
- Feb 26, 2026On February 24, 2026, Bicara Therapeutics Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC, TD Securities (USA) LLC and BofA Securities, Inc., as representatives (the “Representatives”) of the underwriters named therein (the “Underwriters”) …Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Biotechnology
The closest names by size in the same industry